Why Is Neurocrine Biosciences Stock Trading Lower On Friday?

On Thursday, Neurocrine Biosciences Inc. NBIX reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a year ago, beating the consensus of $1.56.The company reported sales of $627.7 million compared to $515.2 million a year ago, missing the consensus of $628.99 million.Ingrezza fourth quarter and fiscal 2024 net product sales were $615 million and $2.3 billion, respectively.Also Read: Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan RightsIngrezza fourth ...